Patents Assigned to Epic Sciences, Inc.
-
Publication number: 20230175073Abstract: Provided herein a method for enhanced assessment of breast cancer in a subject including identification of circulating breast cancer cells in a biological sample and single-cell, whole-genome sequencing of the identified circulating breast cancer cells. Optionally, cell-free tumor DNA is further assessed from the same biological sample or a parallel sample. Also provided are methods of treating a subject with breast cancer using the enhanced assessment to select one or more anti-cancer agents for administering to the subject.Type: ApplicationFiled: December 7, 2022Publication date: June 8, 2023Applicant: EPIC SCIENCES, INC.Inventors: Ernest LAM, Martin BLANKFARD, Nilesh DHARAJIYA, Richard WENSTRUP, Ryon GRAF
-
Publication number: 20230085158Abstract: The invention provides seminal computational approaches utilizing data from non-rare cells to detect rare cells, such as circulating tumor cells (CTCs). The invention is applicable at two distinct stages of CTC detection; the first being to make decisions about data collection parameters and the second being to make decisions during data reduction and analysis. Additionally, the invention utilizes both one and multi-dimensional parameterized data in a decision making process.Type: ApplicationFiled: May 17, 2022Publication date: March 16, 2023Applicants: The Scripps Research Institute, Epic Sciences, Inc.Inventors: Peter Kuhn, Anand Kolatkar, Joshua Kunken, Dena Marrinucci, Xing Yang, John R. Stuelpnagel
-
Patent number: 11340228Abstract: The disclosure provides methods for analyzing rare circulating cells (RCCs) at cellular and molecular level following their detection in non-enriched blood samples, methods of this disclosure serve as diagnostic methods for several disease conditions, including cardiovascular diseases and cancer.Type: GrantFiled: December 11, 2019Date of Patent: May 24, 2022Assignee: Epic Sciences, Inc.Inventor: Dena Marrinucci
-
Publication number: 20200200752Abstract: The invention provides methods for diagnosing prostate cancer. The invention also provides methods for determining the prognosis and efficacy of STEAP1-ADC therapy in patients with prostate cancer, specifically metastatic castration resistant prostate cancer (mCRPC).Type: ApplicationFiled: December 19, 2019Publication date: June 25, 2020Applicants: Genentech, Inc., EPIC SCIENCES INC.Inventors: Omar Kabbarah, Iliana Szafer-Glusman, Dena Marrinucci, Florence Lee, Shannon Werner
-
Patent number: 10613089Abstract: The invention provides seminal computational approaches utilizing data from non-rare cells to detect rare cells, such as circulating tumor cells (CTCs). The invention is applicable at two distinct stages of CTC detection; the first being to make decisions about data collection parameters and the second being to make decisions during data reduction and analysis. Additionally, the invention utilizes both one and multi-dimensional parameterized data in a decision making process.Type: GrantFiled: January 18, 2019Date of Patent: April 7, 2020Assignees: The Scripps Research Institute, Epic Sciences, Inc.Inventors: Peter Kuhn, Anand Kolatkar, Joshua Kunken, Dena Marrinucci, Xing Yang, John R. Stuelpnagel
-
Patent number: 10545151Abstract: The disclosure provides methods for analyzing rare circulating cells (RCCs) at cellular and molecular level following their detection in non-enriched blood samples, methods of this disclosure serve as diagnostic methods for several disease conditions, including cardiovascular diseases and cancer.Type: GrantFiled: February 19, 2015Date of Patent: January 28, 2020Assignee: Epic Sciences, Inc.Inventor: Dena Marrinucci
-
Patent number: 10527624Abstract: The present invention describes a method for detecting castration-resistant prostate cancer (CRPC) in a patient afflicted with prostate cancer comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to detect circulating tumor cells (CTC), (b) determining prevalence of a CTC subpopulation associated with CRPC comprising detecting a measurable feature of each biomarker in a panel of morphological and protein biomarkers, and (c) comparing the prevalence of said CTC subpopulation to a predetermined threshold value, wherein the prevalence of the CTC subpopulation associated with CRPC above said predetermined threshold value is indicative of CRPC. In some embodiments, the CTC subpopulation associated with CRPC comprises CK? CTCs. In some embodiments, the CTC subpopulation associated with CRPC comprises small CTCs.Type: GrantFiled: January 26, 2015Date of Patent: January 7, 2020Assignee: Epic Sciences, Inc.Inventor: Ryan Dittamore
-
Patent number: 10254286Abstract: Methods are provided for detecting 5T4-positive circulating tumor cells in a mammalian subject. Methods of diagnosing 5T4-positive cancer in a mammalian subject are provided. The methods of detection or diagnosis indicate the presence of 5T4-positive metastatic cancer or early stage 5T4-positive cancer.Type: GrantFiled: January 22, 2013Date of Patent: April 9, 2019Assignees: Pfizer Inc., Epic Sciences, Inc.Inventors: Steven Pirie-Shepherd, Hans-Peter Gerber, Dena Marrinucci, Eric Tucker
-
Publication number: 20180209982Abstract: The invention provides methods for diagnosing prostate cancer. The invention also provides methods for determining the prognosis and efficacy of STEAP1-ADC therapy in patients with prostate cancer, specifically metastatic castration resistant prostate cancer (mCRPC).Type: ApplicationFiled: October 20, 2017Publication date: July 26, 2018Applicants: Genentech, Inc., EPIC SCIENCES INC.Inventors: Omar KABBARAH, Iliana SZAFER-GLUSMAN, Dena MARRINUCCI, Florence LEE, Shannon WERNER
-
Publication number: 20170285035Abstract: The disclosure provides a method of predicting de novo resistance to androgen receptor (AR) targeted therapy in a tumor of a prostate cancer patient comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characteristization of nucleated cells in a blood sample obtained from the patient to generate circulating tumor cell (CTC) data, wherein the analysis comprises determining a measurable feature of a panel of traditional and non-traditional CTC biomarkers for de novo resistance to androgen receptor (AR) targeted therapy, and (b) evaluating the CTC data to determine the probability of de novo resistance to the AR targeted therapy in the tumor of the prostate cancer patient. Further disclosed are the panel of traditional and non-traditional CTC biomarkers for the methods.Type: ApplicationFiled: September 24, 2015Publication date: October 5, 2017Applicant: Epic Sciences, Inc.Inventor: Ryan Dittamore
-
Publication number: 20140308669Abstract: The present application provides methods for obtaining single cells from a sample. Methods for isolating and analyzing molecular features obtained from a single cell are also disclosed herein. For example, individual circulating tumor cells (CTCs) from a sample such as a patient's blood sample can be identified and obtained using methods disclosed herein, and picked for further analysis.Type: ApplicationFiled: January 23, 2012Publication date: October 16, 2014Applicant: Epic Science, Inc.Inventors: Xing Yang, David M. Nelson, Peter Kuhn, Daniel Chesnaye Lazar